Sanofi (NASDAQ:SNY) Given Consensus Rating of “Buy” by Brokerages

Sanofi (NASDAQ:SNY) has been given a consensus recommendation of “Buy” by the three brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $60.00.

SNY has been the subject of a number of research reports. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Franklin Resources Inc. grew its holdings in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Natixis Advisors LLC grew its stake in Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after buying an additional 114,133 shares during the last quarter. Raymond James & Associates increased its position in Sanofi by 4.8% in the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after buying an additional 129,472 shares during the period. JPMorgan Chase & Co. lifted its stake in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, DAVENPORT & Co LLC grew its position in shares of Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY stock opened at $54.34 on Friday. The stock’s 50-day moving average price is $49.24 and its 200 day moving average price is $52.27. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The stock has a market capitalization of $137.91 billion, a PE ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. As a group, equities research analysts forecast that Sanofi will post 3.82 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.